It now seems to be premature to define anti-EIF3A autoantibody as early stage cancer biomarker because of the limitation in clinical samples for retrospective or prospective studies; however, further studies on large, well-defined cohort will show its usefulness for cancer diagnosis. This evidence concerns the gene EIF3A and cancer.